Last reviewed · How we verify
Contraceptive Vaginal Ring
Contraceptive Vaginal Ring is a Hormonal contraceptive Small molecule drug developed by Penn State University. It is currently FDA-approved for Contraception in women of reproductive age. Also known as: Nuva Ring.
Releases hormones (typically ethinyl estradiol and a progestin) directly into the vaginal tissue to prevent ovulation and thicken cervical mucus.
The Contraceptive Vaginal Ring is a small molecule contraceptive device that has been studied for various conditions, including HIV infections, breakthrough bleeding, and polycystic ovary syndrome. The ring's mechanism of action is not specified in the provided information, but it is classified as a small molecule modality.
At a glance
| Generic name | Contraceptive Vaginal Ring |
|---|---|
| Also known as | Nuva Ring |
| Sponsor | Penn State University |
| Drug class | Hormonal contraceptive |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
The vaginal ring is a flexible polymer device that continuously releases contraceptive hormones over three weeks. The hormones suppress the luteinizing hormone (LH) surge needed for ovulation, while also altering cervical mucus viscosity to impede sperm transport. This provides systemic contraceptive efficacy with lower hormone doses than oral formulations due to direct vaginal absorption.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Vaginal irritation or discomfort
- Headache
- Nausea
- Breast tenderness
- Vaginal discharge
- Mood changes
Key clinical trials
- A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom (NA)
- Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring (PHASE3)
- Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS (PHASE4)
- Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users (PHASE2)
- A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women (PHASE2)
- Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring (PHASE2)
- Evaluation of Anterior Tibial Knee Translation in Healthy Women With and Without Hormone Therapy (NA)
- Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Contraceptive Vaginal Ring CI brief — competitive landscape report
- Contraceptive Vaginal Ring updates RSS · CI watch RSS
- Penn State University portfolio CI
Frequently asked questions about Contraceptive Vaginal Ring
What is Contraceptive Vaginal Ring?
How does Contraceptive Vaginal Ring work?
What is Contraceptive Vaginal Ring used for?
Who makes Contraceptive Vaginal Ring?
Is Contraceptive Vaginal Ring also known as anything else?
What drug class is Contraceptive Vaginal Ring in?
What development phase is Contraceptive Vaginal Ring in?
What are the side effects of Contraceptive Vaginal Ring?
Related
- Drug class: All Hormonal contraceptive drugs
- Manufacturer: Penn State University — full pipeline
- Therapeutic area: All drugs in Contraception / Reproductive Health
- Indication: Drugs for Contraception in women of reproductive age
- Also known as: Nuva Ring
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing